GSK settles Augmentin dispute with Novartis
Novartis has agreed to pay GlaxoSmithKline a royalty on sales of a generic version of GSK's antibiotic Augmentin (amoxicillin/clavulanate) sold in the USA as AmoxC.
Archives for July 9, 2003
New approach to molecular modelling
A technique known as electron momentum spectroscopy may provide a means of improving rational drug design by allowing direct measurement of the wavefunction of large molecules.
Roche escapes Igen damages, but loses ECL rights
A US appeals court has reversed an earlier decision to make Switzerland's Roche pay almost $500 million in damages to Igen in a dispute over a technology used in clinical diagnostics and pharmaceutical research.
Crestor clears FDA panel
Crestor (rosuvastatin), the 'superstatin' developed by AstraZeneca, has been recommended for approval by a US Food and Drug Administration advisory panel.
Symphogen strengthens Ab patent position
Danish biotech company Symphogen has obtained a European patent on its Symphage technology for the development of antibody-based drugs. Clinical trials of the product candidate are due to start in 2005.